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Downregulation of MHC class I on the cell surface is
an immune evasionmechanism shared bymany DNA
viruses, including cowpox virus. Previously, a cow-
pox virus protein, CPXV203, was shown to downre-
gulate MHC class I. Here we report that CPXV12 is
the only other MHC class I-regulating protein of cow-
pox virus and that it uses a mechanism distinct from
that of CPXV203. Whereas CPXV203 retains fully
assembled MHC class I by exploiting the KDEL-
mediated endoplasmic reticulum retention pathway,
CPXV12 binds to the peptide-loading complex and
inhibits peptide loading on MHC class I molecules.
Viruses deleted of both CPXV12 and CPXV203
demonstrated attenuated virulence in a CD8 T cell-
dependent manner. These data demonstrate that
CPXV12 and CPXV203 proteins combine to ablate
MHC class I expression and abrogate antiviral CD8
T cell responses.
INTRODUCTION
Major histocompatibility complex (MHC) class I molecules play
a critical role in antiviral immunity. A MHC class I molecule is
composed of a heavy chain, a b2-microglobulin (b2m) light chain,
and a peptide of 8–10 amino acids in length. The majority of MHC
class I-binding peptides is generated in the cytosol by protea-
somes and transported into the lumen of the endoplasmic retic-
ulum (ER) by transporter associated with antigen processing
(TAP). Peptide loading onto the MHC class I heavy chain-b2m
heterodimer is facilitated by a multisubunit protein complex
called the MHC class I peptide-loading complex (PLC) (Peaper
and Cresswell, 2008). In addition to TAP and MHC class I, the
PLC is composed of ER chaperones such as tapasin, ERp57,
calreticulin, and protein disulfide isomerase. Upon peptide422 Cell Host & Microbe 6, 422–432, November 19, 2009 ª2009 Elseloading, the fully assembled MHC class I complexes dissociate
from the PLC and transit to the cell surface. Recognition of viral
peptides in the context of MHC class I molecules triggers virus-
specific CD8 T cells to exert their effector functions, including
cytotoxicity and cytokine secretion (Guidotti and Chisari, 1996).
To avoid detection by CD8 T cells, viruses have evolved
various mechanisms to interfere with MHC class I antigen
presentation (Hansen and Bouvier, 2009). Some viruses accel-
erate MHC class I turnover. Human cytomegalovirus (HCMV)
US2 and US11 cause proteasomal degradation of MHC class I
molecules by retrograde transport from the ER to the cytosol
(Wiertz et al., 1996a, 1996b). The mK3 protein of murine
gamma-herpesvirus 68 (MHV-68) induces proteasomal degra-
dation of MHC class I as well as other components of the PLC
(Boname et al., 2004; Lybarger et al., 2003; Stevenson et al.,
2000). Kaposi’s sarcoma-associated herpesvirus (KSHV) K3 and
K5, murine cytomegalovirus (MCMV) m06/gp48, and myxoma
virus leukemia-associated protein induce lysosomal degradation
of MHC class I (Coscoy and Ganem, 2000; Guerin et al., 2002;
Ishido et al., 2000; Reusch et al., 1999; Zuniga et al., 1999). An
alternative strategy is retention of MHC class I molecules in the
ER or ER-Golgi intermediate compartments. Adenoviruses E3/
19K, HCMV US3, and MCMV m152/gp40 fall into this category
(Ahn et al., 1996a; Andersson et al., 1985; Jones et al., 1996;
Liu et al., 2007; Ziegler et al., 1997). TAP appears to be an attrac-
tive target for viral inhibition of MHC class I biosynthesis. Herpes
simplex virus (HSV) ICP-47 (Fruh et al., 1995; Hill et al., 1995;
York et al., 1994), HCMV US6 (Ahn et al., 1997; Hengel et al.,
1997; Lehner et al., 1997), varicellovirus UL49.5 (Koppers-Lalic
et al., 2005; Koppers-Lalic et al., 2008), and BNLF2a of Epstein-
Barr virus (Hislop et al., 2007) were shown to interfere with TAP
function to limit the supply of peptides for loading onto MHC
class I. These viral inhibitors of MHC class I expression have
yielded insight into normal MHC class I synthesis and assembly.
The in vivo significance of these viral MHC class I evasion
mechanisms, however, is not well understood and is somewhat
controversial. In a mouse model of HSV-1, ICP-47 was shown to
enhance neurovirulence (Goldsmith et al., 1998). However, thesevier Inc.
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minimal effect on murine MHC class I (Ahn et al., 1996b).
MHV-68 and MCMV, on the other hand, efficiently inhibit murine
MHC class I. Whereas mK3-deficient MHV-68 failed to establish
a normal latent load (Stevenson et al., 2002), MCMV lacking all
known MHC class I evasion genes (m04, m06, m152) did not
demonstrate attenuated virulence unless they were tested in
immunocompromised or newborn mice (Doom and Hill, 2008).
Furthermore, to our knowledge, it has not been clearly demon-
strated how the evasion of MHC class I antigen presentation
affects the pathogenesis of nonherpesviruses.
In this regard, it is noteworthy that cowpox virus (CPXV) has
recently been shown to downregulate MHC class I and evade
antiviral CD8 T cell responses (Dasgupta et al., 2007). CPXV
belongs to Orthopoxvirus genus of the poxvirus family, which
also includes other clinically important pathogens such as variola
virus, the causative agent of smallpox, and monkeypox virus.
Wild rodents are believed to be the natural reservoir hosts of
CPXV in Europe (Chantrey et al., 1999). Like other orthopoxvi-
ruses, CPXV encodes a large number of immune evasion genes
in its DNA genome (Seet et al., 2003). One such gene, CPXV203,
was shown to have a role in MHC class I downregulation by
CPXV (Byun et al., 2007). It was identified by screening murine
cell lines expressing selected candidate viral genes for gain of
function, i.e., MHC class I downregulation. We demonstrated
that CPXV203 interferes with the intracellular trafficking of
MHC class I molecules by sequestering them in the ER using
its C-terminal KDEL-like sequence. However, CPXV203-defi-
cient virus (CPXVD203) still efficiently downregulated MHC class
I molecules on the cell surface, indicating the virus encodes
another, yet-to-be-identified, MHC class I modulator(s).
Here, we report that CPXV12 is responsible for the residual
MHC class I downregulation by CPXVD203. Based on biochem-
ical studies, we demonstrate that CPXV12 inhibits MHC class I
expression by impairing ER peptide loading and dissociation of
MHC class I from TAP. Importantly, using a mouse model, we
provide evidence that MHC class I downregulation by CPXV12
and CPXV203 contributes to CPXV virulence by ablating antiviral
CD8 T cell responses.
RESULTS
Identification of CPXV12 by Loss-of-Function Screening
To find another CPXV gene(s) with MHC class I-downregulating
activity, we undertook a strategy different from that used to iden-
tify CPXV203. In a loss-of-function screening approach, we
examined A518, a CPXV mutant in which 28.5 kb region between
the ClaI sites at positions 10642 and 39152 had been deleted
(Figure 1A). Since A518 contains intact CPXV203, we generated
its derivative deleted of CPXV203 (A518D203) to investigate
CPXV203-independent MHC class I-downregulating activity
(Figure 1A). Murine fibroblast MC57G cells were infected with
A518D203, and their surface MHC class I levels were compared
to those of CPXVD203-infected cells. GFP inserted in the
CPXV203 locus enabled detection of the virus-infected cells by
flow cytometry. Downregulation of Kb and Db was observed in
CPXVD203-infected cells, as we previously reported, but not in
A518D203-infected cells (Figure 1B). These data indicated the
genomic region deleted in A518 contains the gene(s) responsibleCell Hosfor the residual MHC class I-downregulating activity of
CPXVD203.
The genomic region deleted in A518 contains 26 open reading
frames (ORFs) from CPXV11 to CPXV36. To map the MHC class
I-downregulating activity among these ORFs, we split them into
twogroups, CPXV11-21 and CPXV22-36,and generated recombi-
nant viruses specifically lacking each group of genes in addition
to CPXV203. When these viruses were tested for the ability to
downregulate Kb, CPXVD11-21D203, but not CPXVD22-36D203,
recapitulated the loss-of-function phenotype of A518D203, nar-
rowing down the candidate region to CPXV11-CPXV21 (Fig-
ure 1C). After four iterative rounds of paired deletion mutant
screening, we found that deletion of the genomic region encoding
CPXV12 is sufficient to prevent Kb downregulation by CPXVD203
(Figures 1C and 1D). Similarly, CPXVD203-mediated downregula-
tion of Db and Dk was abrogated by the deletion of CPXV12
(Figure 1D). Therefore, CPXV12 is responsible for the CPXV203-
independent MHC class I-downregulating activity of CPXV.
CPXV12 Delays the Intracellular Trafficking of MHC
Class I
The loss of MHC class I-downregulating activity by the deletion
of CPXV12 did not exclude the possibility that the protein
encoded by CPXV12 might depend on other viral proteins for
its function. To investigate this issue, we expressed CPXV12 in
the absence of other CPXV proteins in murine lymphoblast
C1498 cells using a bicistronic retroviral expression vector con-
taining an internal ribosomal entry site followed by GFP. There
was good correlation between the expression of CPXV12, which
was inferred from GFP expression, and the reduction of Kb and
Db levels, demonstrating that CPXV12 is sufficient for MHC class
I downregulation (Figure 2A).
The deduced sequence of CPXV12 consists of 69 amino acids
and does not exhibit any similarity with other viral or mammalian
proteins except its orthologs in CPXV strain GRI-90, Germany
91-3, and ectromelia virus (ECTV) strain Moscow. Sequence
homology between CPXV12 and its poxvirus orthologs is signif-
icant only for the N-terminal region, which contains a putative
transmembrane domain (see Figure S1A available online).
Expression of the ECTV ortholog EVM007 in C1498 cells did
not induce MHC class I downregulation (Figure S1B), suggesting
the function of CPXV12 might have diverged from that of its
orthologs during evolution.
To understand the mechanism by which CPXV12 modulates
MHC class I expression, we monitored the biosynthesis of
MHC class I by pulse-chase experiments. Similar amounts of
Kb heavy chains were synthesized in vector- and CPXV12-trans-
duced cells during the labeling period, indicating the de novo
synthesis of MHC class I was unaffected by CPXV12 (Figure 2B,
chase 0 min). However, we found markedly slower accumulation
of Endo H-resistant Kb (Figure 2B) and Db (data not shown) in
CPXV12-transduced cells. Since glycoproteins acquire Endo
H-resistance during transit through the Golgi, these data indi-
cated CPXV12 inhibits the intracellular trafficking of newly
synthesized MHC class I molecules.
Consistent with these data, the steady-state level of Endo
H-resistant Kb heavy chain was markedly lower in CPXV12-ex-
pressing cells (CPXV12-transduced C1498 cells or CPXVD203-
infected MC57G cells) compared to their respective control cellst & Microbe 6, 422–432, November 19, 2009 ª2009 Elsevier Inc. 423
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MC57G cells) (Figure 2C). Together, these results suggested
that the reduction of MHC class I levels on the cell surface is likely
due to a defect in intracellular trafficking induced by CPXV12.
CPXV12 Inhibits the Release of MHC Class I
from the PLC
We hypothesized that the delayed trafficking of MHC class I
molecules in CPXV12-expressing cells might be due to PLC
dysfunction, since the PLC is responsible for the quality control
of MHC class I assembly, ensuring only optimally assembled
MHC class I molecules are released from the ER. To test this
hypothesis, we first examined whether CPXV12 physically inter-
Figure 1. Identification of CPXV12 by Loss-
of-Function Screening
(A) Schematic diagram of CPXV mutants.
Numbers indicate positions in kilobase (kb) corre-
sponding to the wild-type CPXV strain Brighton
Red genome. CPXV203 was replaced with GFP
in CPXVD203 and A518D203.
(B) MC57G cells infected with indicated CPXV
mutants were analyzed for surface Kb or Db
expression at 24 hr postinfection.
(C) MC57G cells infected with CPXV mutants indi-
cated above each histogram were harvested at
24 hr postinfection, and their surface Kb expres-
sion levels were compared to those of CPXVD203-
or A518D203-infected cells.
(D) MC57G cells (Kb, Db) and L929 cells (Dk) were
infected with CPXVD203 or CPXVD12D203 and
analyzed for MHC class I expression at 24 hr post-
infection.
acts with the PLC by coimmunoprecipita-
tion experiments. CPXV12 tagged with a
hemagglutinin (HA) epitope at the C ter-
minus (CPXV12-HA) was expressed in
C1498 cells. Precipitation of CPXV12-
HA with anti-HA antibody coprecipitated
TAP1, tapasin, and Kb heavy chain (Fig-
ure 3A). Reciprocally, immunoprecipita-
tion with anti-TAP1 serum coprecipitated
CPXV12-HA along with other compo-
nents of the PLC (Figure 3A). Together,
these results suggested that CPXV12
physically associates with the PLC with-
out disrupting its overall assembly.
Examination of the anti-TAP1 precipi-
tates also revealed that the levels of
TAP1, tapasin, and calreticulin in the
PLC were unaffected, whereas the level
of PLC-associated Kb heavy chain was
dramatically increased in CPXV12-trans-
duced cells (Figure 3A). These results
were further validated by performing
similar experiments with CPXV-infected
cells. The level of PLC-associated Kb
heavy chain was strikingly higher in
CPXVD203-infected cells (CPXV12-suffi-
cient) compared to CPXVD12D203-infected cells (CPXV12-defi-
cient) (Figure 3A).
To investigate this further, we examined the kinetic profile of
PLC-MHC class I interaction. In vector-transduced cells, the
level of PLC-associated Kb heavy chain peaked at 10 min after
the initial synthesis and then gradually diminished over time
(Figure 3B). This pattern was consistent with the transient inter-
action between the newly synthesized MHC class I molecules
and the PLC during the peptide-loading process. In CPXV12-
transduced cells, the level of PLC-associated Kb also peaked
at 10 min, but it was sustained for at least 50 min without
decrease (Figure 3B). These data demonstrated that CPXV12
inhibits the dissociation of MHC class I molecules from the PLC.424 Cell Host & Microbe 6, 422–432, November 19, 2009 ª2009 Elsevier Inc.
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The prolonged interaction between MHC class I and the PLC in
CPXV12-transduced cells suggested a defect in the peptide-
loading process. To test this, we evaluated the thermostability
of peptide-MHC class I complex, which has been shown to
reflect peptide affinity (Bouvier and Wiley, 1994; Fahnestock
et al., 1992; Schumacher et al., 1990; Williams et al., 2002).
Most Kb molecules in vector-transduced cells withstood 37C
incubation without losing their intact conformation, whereas Kb
molecules in CPXV12-transduced cells failed to maintain their
conformation unless they were preincubated with high-affinity
peptide VNVDYSKL (Figure 4A). These results suggested that
MHC class I molecules in CPXV12-transduced cells were loaded
with suboptimal peptides.
Furthermore, we found that MHC class I molecules in
CPXV12-transduced cells were peptide receptive. Exogenously
added SIINFEKL peptides that bind to Kb with high affinity
restored the surface expression of Kb in CPXV12-transduced
cells in a dose-dependent manner (Figure 4B). This was due to
a specific interaction between MHC class I and its cognate
Figure 2. CPXV12 Delays MHC Class I Traf-
ficking
(A) Surface expression levels of Kb and Db were
measured in C1498 cells transduced with either
vector alone or CPXV12. GFP serves as a marker
for transduction.
(B) Intracellular trafficking of Kb molecules was
examined in the presence and absence of
CPXV12. C1498 cells transduced with either
vector alone or CPXV12 were sorted several times
until the GFP-positive population was >95% (data
not shown). They were labeled with [35S]-Met/Cys
for 10 min and chased for the indicated periods of
time. Kb molecules were immunoprecipitated from
cell lysates and treated with Endo H prior to SDS-
PAGE. The proportion of Endo H-resistant form at
each chase time point was plotted. A representa-
tive result of three independent experiments is
shown. EH-R, Endo H resistant; EH-S, Endo H
sensitive.
(C) C1498 cells transduced with either vector
alone or CPXV12 were sorted several times until
the GFP-positive population was >95% (data not
shown). MC57G cells were infected with either
CPXVD12D203 or CPXVD203 at a moi of 3. Cell
lysates were treated with Endo H where indicated,
and Kb heavy chain was detected by immunoblot-
ting.
Figure 3. CPXV12 Inhibits MHC Class I
Dissociation from the PLC
(A) Digitonin lysates of C1498 cells transduced
with either vector alone or CPXV12 (left four lanes)
and of MC57G cells infected with either
CPXVD12D203 or CPXVD203 (right two lanes)
were subjected to immunoprecipitation with anti-
HA or anti-TAP1 serum. Precipitated proteins
were separated by SDS-PAGE and blotted for
indicated proteins. ND, not determined.
(B) C1498 cells transduced with either vector alone
or CPXV12 were labeled with [35S]-Met/Cys for
10 min and then chased for the indicated periods
of time. Cells were lysed with 1% digitonin and
subjected to immunoprecipitation with anti-TAP1
serum. From the coprecipitated proteins, Kb was
further purified by reimmunoprecipitation with
anti-Kb serum. Protein bands corresponding to
Kb heavy chain (HC) and b2m are indicated.
Asterisk (*) indicates nonspecific protein. The
levels of Kb heavy chain at each time point
compared to the initial amounts (set as 100%)
are plotted in the bottom graph. Mean ± standard
error of mean (SEM) from two independent exper-
iments is shown.Cell Host & Microbe 6, 422–432, November 19, 2009 ª2009 Elsevier Inc. 425
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(A) C1498 cells transduced with indicated constructs were labeled with [35S]-Met/Cys for 10 min and chased for 60 min. Cell lysates were incubated with indicated
concentrations of peptide VNVDYSKL at 4C for 30 min and subsequently incubated at 37C for 30 min. Kb was immunoprecipitated with monoclonal antibody
B8-24-3, which recognizes peptide-bound Kb. Band intensities were quantified and plotted as percent of maximum, which represents the amount of Kb before the
37C incubation (set as 100%). Mean ± SEM from three independent experiments is shown.
(B) C1498 cells transduced with vector alone or CPXV12 were incubated with indicated concentrations of SIINFEKL or ASNENMETM peptide in the culture
medium for 16 hr at 37C and analyzed for surface Kb expression by flow cytometry.
(C) Peptide transport activity of TAP was assessed in C1498 cells transduced with vector alone, BHV-1 UL49.5, or CPXV12. Translocation of the fluorescently
labeled peptide CVNKTERAY was evaluated in the presence or absence of ATP. Peptide transport is expressed as percentage of translocation, relative to the
translocation observed in control cells (set as 100%). Statistical significance was determined by Student’s t test.
(D) Surface levels of Kb and Db were compared between C1498 cells transduced with indicated constructs.426 Cell Host & Microbe 6, 422–432, November 19, 2009 ª2009 Elsevier Inc.
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ASNENMETM had no effect on Kb expression (Figure 4B),
whereas it restored Db expression (data not shown). Together,
these data suggested that CPXV12 inhibits optimal peptide
loading on MHC class I.
Impaired peptide loading could be a result of insufficient
peptide supply in the ER. The majority of MHC class I-binding
peptides are transported from the cytosol into the ER by TAP,
and we found a statistically significant reduction of TAP-depen-
dent peptide transport activity in CPXV12-transduced C1498
cells (Figure 4C). However, the reduction was rather modest,
especially compared to the effect of UL49.5 (Figure 4C), a potent
inhibitor of TAP encoded by bovine herpesvirus 1 (BHV-1) (Kop-
pers-Lalic et al., 2005). Yet we observed a similar degree of MHC
class I downregulation in UL49.5- and CPXV12-expressing cells
(Figure 4D), suggesting CPXV12 has additional mechanisms of
impairing peptide loading independent of regulating peptide
supply.
Notably, CPXV203 did not compromise the thermostability of
Kb (Figure 4A), which was in line with the previous observation
that exogenously added peptides did not reverse MHC class I
downregulation by CPXV203 (Byun et al., 2007). Together, these
results indicate that CPXV12 and CPXV203 use different mech-
anisms to block MHC class I expression. CPXV12 engages
MHC class I prior to full assembly and impairs peptide binding
and TAP dissociation, whereas CPXV203 engages MHC class I
after TAP dissociation and exploits an ER retrieval pathway.
Evasion of CD8 T Cells by CPXV12 and CPXV203
The discovery that CPXV encodes two proteins that downregu-
late MHC class I with distinct mechanisms prompted us to inves-
tigate the relative contribution of each of these proteins in MHC
class I regulation and in vivo infection. MC57G cells infected with
wild-type CPXV (wtCPXV) or viruses deleted of either or both
CPXV12 and CPXV203 (CPXVD12, CPXVD203, CPXVD12D203)
were compared for their MHC class I levels on the cell surface.
To ensure the multiplicity of infection was comparable between
the viruses, poxvirus HA levels were measured as controls. Dele-
tion of either CPXV12 or CPXV203 alone did not have a notable
effect except the partial increase of Kb expression by the deletion
of CPXV203 compared to wtCPXV (Figure 5A). However, dele-
tion of both proteins completely abrogated the downregulation
of Kb and Db by CPXV, confirming that they are the only compo-
nents of CPXV involved in MHC class I downregulation.
Since a primary role of MHC class I molecules is presenting
antigens to CD8 T cells, we examined the effect of CPXV12
and CPXV203 on the antiviral CD8 T cell response. Splenocytes
from wtCPXV-infected C57BL/6 mice were harvested at day 7
postinfection and stimulated with MC57G cells that were in-
fected with wtCPXV or CPXV deletion mutants in vitro. We found
good correlation between the MHC class I levels on the target
cells and the size of CD8 T cell responses. MC57G cells infected
with wtCPXV or CPXVD12, which displayed very low levels of
Kb and Db (Figure 5A), were extremely poor at stimulating CD8
T cells for IFN-g production (Figures 5B and 5C) or cytotoxicity
(Figure 5D). In comparison, CPXVD203-infected MC57G cells,
which expressed higher levels of Kb than wtCPXV- or
CPXVD12-infected cells (Figure 5A), triggered a larger number
of CD8 T cells to produce IFN-g and exert cytotoxicity (Fig-
ures 5B–5D). Importantly, CPXVD12D203-infected cells, which
expressed much higher levels of Kb and Db than any other
virus-infected group, were most efficient at stimulating IFN-g
production and cytotoxicity of CD8 T cells (Figures 5B–5D).
Together, these results demonstrated that CPXV12 and
Figure 5. Evasion of Antiviral CD8 T Cell
Responses by CPXV12 and CPXV203
C57BL/6 mice were intranasally infected with 1 3
104 PFU of wtCPXV. Splenocytes were harvested
at day 7 postinfection. MC57G cells were mock
infected or infected with indicated viruses at a
moi of 2 for 18 hr.
(A) Surface expression levels of Kb, Db, and
poxvirus HA on MC57G cells were analyzed by
flow cytometry.
(B) Splenocytes were incubated with MC57G cells
for 7 hr and analyzed for IFN-g by intracellular
staining followed by flow cytometry. Numbers
indicate percentage of IFN-g+ cells among total
CD8+ lymphocytes. A representative result of
three similar experiments is shown.
(C) Same as in (B), except mean ± SEM from three
independent experiments is shown. Statistical
significance was determined by Student’s t test.
*, p < 0.05; ns, not significant.
(D) Splenocytes were coincubated with 51Cr-
labeled MC57G cells for 4 hr. Lysis of MC57G cells
was measured by 51Cr-release assay. E/T repre-
sents effector (splenocytes) to target (MC57G
cells) ratio. Mean ± SEM from three independent
experiments is shown.Cell Host & Microbe 6, 422–432, November 19, 2009 ª2009 Elsevier Inc. 427
Cell Host & Microbe
MHC Class I Downregulation by Cowpox VirusCPXV203 protect CPXV-infected cells from antiviral CD8 T cell
responses, likely by downmodulating MHC class I.
CPXV12 and CPXV203 Contribute to Virulence
by Evading CD8 T Cells In Vivo
To investigate the in vivo roles of CPXV12 and CPXV203, naive
9-week-old C57BL/6 mice were infected with 5 3 104 PFU of
wtCPXV, CPXVD12D203, or revertant virus (CPXVR12R203) via
an intranasal route and monitored for survival. All mice infected
with either wtCPXV or CPXVR12R203 succumbed to disease
between 9 and 14 days postinfection, while 19 of 20 (95%)
CPXVD12D203-infected mice survived (Figure 6A). These data
clearly demonstrated the important contributions of CPXV12
and CPXV203 in CPXV virulence in the host.
The attenuation of CPXVD12D203 could be due to a loss of
intrinsic replication potential. However, in Vero cells cultured
in vitro, CPXVD12D203 replicated with similar kinetics compared
to wtCPXV and CPXVR12R203 as measured by one-step growth
curve (Figure 6B), indicating CPXV12 and CPXV203 are not
essential for intracellular virus replication. Furthermore, we
did not find a significant difference in spleen titers between
wtCPXV- or CPXVD12D203-infected groups at day 7 postinfec-
tion (Figure 6C), which also argued against an intrinsic defect
in replication as the reason for the decreased virulence of
CPXVD12D203. Rather, the significantly lower viral titers in
CPXVD12D203-infected animals at day 10 postinfection sug-
gested that the host immune system could clear the viruses
Figure 6. CPXV12 and CPXV203 Abrogate
CD8 T Cell Immunity against CPXV In Vivo
(A) Nine-week-old C57BL/6 mice were infected
intranasally with 5 3 104 PFU of the indicated
viruses and monitored for survival. Results were
pooled from two independent experiments.
(B) One-step growth curves for the indicated
viruses were obtained in Vero cells. Genome
copy numbers were determined by quantitative
PCR. Mean ± SEM of triplicates is shown.
(C) Nine-week-old C57BL/6 mice were infected
intranasally with indicated viruses. Spleens from
infected mice were harvested at day 7 or day 10
postinfection, and the viral loads were determined
by quantitative PCR. Dotted lines indicate limits of
detection. Statistical significance was determined
by Student’s t test.
(D) Nine-week-old C57BL/6 mice were infected
intranasally with 1 3 104 PFU of the indicated
viruses and monitored for survival. Starting 2
days prior to infection, mice were treated with
1 mg of either isotype-control or CD8-depleting
antibody every fourth day throughout the moni-
toring period. Results were pooled from two inde-
pendent experiments.
more efficiently in the absence of
CPXV12 and CPXV203 (Figure 6C).
Based on these in vivo data as well as
the in vitro data examining the influence
of CPXV12 and CPXV203 on the antiviral
functions of CD8 T cells, we hypothesized
that the attenuation of CPXVD12D203
might be due to its inability to evade CD8 T cells. To test this
hypothesis, we compared the virulence of wtCPXV and
CPXVD12D203 in CD8-depleted mice. C57BL/6 mice treated
with either isotype control or CD8-depleting antibody were
infected with 1 3 104 PFU of wtCPXV or CPXVD12D203. In
control-depleted mice, CPXVD12D203 was less virulent than
wtCPXV (Figure 6D), consistent with the data obtained with
higher dose of virus inoculum (Figure 6A). By contrast, in CD8-
depleted mice, CPXVD12D203 was no longer attenuated
compared to wtCPXV (Figure 6D). Furthermore, the comparison
of mortality rates between control- or CD8-depleted groups
demonstrated that CD8 T cells had little protective effect against
CPXV in the presence of CPXV12 and CPXV203, whereas they
were protective in the absence of CPXV12 and CPXV203
(Figure 6D). Together, these data provide compelling evidence
that CPXV12 and CPXV203 contribute to CPXV virulence by
inhibiting the antiviral CD8 T cell responses.
DISCUSSION
CPXV203 was the first CPXV protein shown to be involved in
MHC class I downregulation, but the deletion of CPXV203 did
not fully abolish the phenotype, indicating CPXV encodes
another protein with similar function. Here we mapped the
CPXV203-independent MHC class I-downregulating activity of
CPXV to CPXV12 by loss-of-function screening of deletion
mutant viruses. Furthermore, we showed that expression of428 Cell Host & Microbe 6, 422–432, November 19, 2009 ª2009 Elsevier Inc.
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for MHC class I downregulation. Together, these results provide
genetic and biochemical evidence that CPXV12 is a bona fide
immunomodulatory gene targeting MHC class I molecules.
Our combined data illustrate the mechanism by which
CPXV12 inhibits MHC class I expression on the cell surface.
CPXV12 does not affect the initial translation of MHC class I
molecules, but it delays their maturation. The poor thermosta-
bility of MHC class I in CPXV12-expressing cells suggests that
CPXV12 inhibits peptide loading, which also explains the reten-
tion of MHC class I molecules by the PLC. A clear coprecipitation
of CPXV12 with the PLC strongly suggests CPXV12 interacts
with one or more component(s) of the PLC, which has yet to
be identified, but the interaction does not disrupt the assembly
of the PLC. Since tapasin is required for stable expression of
TAP, this finding rules out the possibility that the modest inhibi-
tion of peptide transport by TAP results from CPXV12 disrupting
tapasin/TAP interaction. Thus we favor the notion that CPXV12
interferes with peptide loading by binding to either tapasin or
MHC class I and impairs tapasin-facilitated peptide binding to
MHC class I. If this model is correct, further investigation of
CPXV12 might shed a light on our understanding of the molec-
ular details of how the PLC orchestrates peptide loading of
MHC class I and what induces the dissociation of fully assem-
bled MHC class I from TAP.
Viruses deleted of both CPXV12 and CPXV203 exhibited
a complete loss-of-function phenotype, indicating the two pro-
teins are the major effectors of CPXV-mediated MHC class I
downregulation. Interestingly, they are structurally and mecha-
nistically divergent. They do not share sequence homology
either at the nucleotide or at the amino acid level. They have
different topologies; CPXV12 is likely a type II-membrane protein
with a short cytoplasmic domain (10 residues) and a longer
luminal domain (34 residues), whereas CPXV203 is likely
a soluble protein with a cleavable N-terminal signal peptide.
The mechanisms by which they interfere with MHC class I
biosynthesis are also different. CPXV12 impairs peptide loading,
while CPXV203 exploits a physiologic ER retention mechanism
to retain peptide-loaded MHC class I molecules in the ER.
Thus, CPXV12 and CPXV203 must have evolved independently
rather than sharing a common ancestor, and yet they have
acquired similar function, implying the importance of MHC class I
antigen presentation and antiviral CD8 T cell response in host
defense against CPXV.
The effects of CPXV12 and CPXV203 on sequential steps of
MHC class I biosynthesis pathway suggest that they may work
synergistically. Limiting the number of peptide-loaded MHC
class I molecules in the ER by CPXV12 would reduce the burden
of CPXV203, allowing tighter control of MHC class I trafficking.
Furthermore, the two proteins may have a different allele-
specific hierarchies in their effects on MHC class I expression,
as was observed for the various MHC class I inhibitors encoded
by HCMV (Machold et al., 1997) or MCMV (Wagner et al., 2002).
Such complementation between the two proteins will ensure
broad yet potent MHC class I-downregulating activity and coun-
terbalance evolution of host MHC class I molecules to avoid
effects of any single CPXV protein.
Identification of all major CPXV proteins involved in MHC
class I downregulation allowed us to examine the physiologicalCell Hostrole of this immune evasion mechanism. The superior virulence
of wtCPXV compared to CPXVD12D203 in wild-type mice, but
not in CD8 T cell-depleted mice, demonstrates that CPXV12
and CPXV203 enhance CPXV virulence by abrogating antiviral
CD8 T cell responses. Interestingly, depletion of CD8 T cells
had little effect against wtCPXV. This may seem paradoxical,
since the premise of MHC class I downregulation is to block anti-
viral CD8 T cell responses. However, by removing CPXV12 and
CPXV203, we were able to confirm that CD8 T cells confer
protection against CPXV in vivo. The critical role of CD8 T cells
was also demonstrated for ECTV, an orthopoxvirus closely
related to CPXV, which does not encode any known evasion
mechanism targeting MHC class I molecules. Like in the
CPXVD12D203-infected animals, depletion of CD8 T cells was
detrimental for the survival of ECTV-infected animals (Karupiah
et al., 1996). Taken together, these data highlight the remarkable
ability of CPXV12 and CPXV203 to neutralize antiviral immunity
mediated by CD8 T cells.
Although the molecular mechanisms of MHC class I downre-
gulation encoded by other viruses have been extensively
studied, demonstrating the in vivo significance has been chal-
lenging. We think our experimental system is ideal to study the
in vivo role of virus-induced MHC class I downregulation for
several reasons. First, mice are biologically relevant hosts for
CPXV, since the natural reservoirs of CPXV are wild rodents.
Second, the C57BL/6 strain of mice used for our studies express
MHC class I molecules of H-2b haplotype, which are very
susceptible to CPXV-induced downregulation. Third, CPXV
seems to have effective measures to counteract NK cells. While
MHC class I downregulation prevents activation of CD8 T cells, it
provokes NK cells due to the reduced engagement of NK inhib-
itory receptors. This could potentially ‘‘neutralize’’ the in vivo
phenotype caused by the effect on CD8 T cells. However, in
CD8-depleted animals, where MHC class I downregulation
would only affect the NK cell response, we did not find difference
in virulence between wtCPXV and CPXVD12D203. Perhaps this
is due to other CPXV immunomodulatory proteins, such as
orthopoxvirus MHC class I-like protein (OMCP), which acts as
a competitive antagonist of an NK cell-activating receptor
NKG2D (Campbell et al., 2007). Together, these factors allowed
us to clearly demonstrate the significant impact of MHC class I
downregulation on the disease outcome.
The data presented here also have interesting implications on
the relative contribution of direct priming versus cross-priming in
generation of antiviral CD8 T cells during CPXV infection. We
noted that CPXV-primed CD8 T cells are easily detectable in
the spleens of wtCPXV-infected mice. Since MHC class I down-
regulation is predicted to disable direct priming, this result
suggests an active role of cross-priming. In any case, the find-
ings reported here further accentuate the value of the CPXV
model system to study host-pathogen interactions.
EXPERIMENTAL PROCEDURES
Cell Lines and Virus
Cell lines MC57G, C1498, Vero, and CV-1 were obtained from American Type
Culture Collection (ATCC) and cultured in ATCC-recommended media. CPXV
strain Brighton Red (CPXV-BR) was obtained from ATCC and propagated in
Vero cells. Viruses were purified from the infected Vero cell lysates by& Microbe 6, 422–432, November 19, 2009 ª2009 Elsevier Inc. 429
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plaque assay using CV-1 cells.
Flow Cytometry
The following monoclonal antibodies were used for flow cytometry: 28-14-8 for
Db (Abcam), AF6-88.5 for Kb, KH95 for Db, XMG1.2 for IFN-g (all from BD
Biosciences), 53-6.7 for CD8a (eBioscience), and IH831 (a gift of G. Karupiah,
Australian National University) for poxvirus HA. For intracellular staining of
IFN-g, cells were fixed and permeabilized using Cytofix/Cytoperm solution
(BD Biosciences). All flow cytometric data were collected using a FACSCalibur
(BD Biosciences) and analyzed with FlowJo software (Tree Star).
Generation of Recombinant Viruses
A518 is a deletion variant of CPXV-BR in which the 28.5 kb region between the
ClaI sites at positions 10,642 and 39,152 have been replaced with the select-
able marker gene Escherichia coli guanine phosphoribosyltransferase (gpt).
The detailed protocol of A518 generation is described in the Supplemental
Data. A518D203, a derivative of A518 with deletion of CPXV203, was gener-
ated using a method previously described for the generation of CPXVD203
(Byun et al., 2007).
To generate the recombinant viruses used for the mapping experiments
(CPXVD11-21D203, CPXVD22-36D203, CPXVD11-17D203, CPXVD18-
21D203, CPXVD11-15D203, CPXVD16-17D203, CPXVD11-12D203, CPXVD13-
15D203, CPXVD11D203, and CPXVD12D203), 50 and 30 flanking sequences
(each 500 bp long) of the genomic regions targeted for deletion were cloned
from CPXV genomic DNA into pBluscriptII (Stratagene). Between the flanking
sequences, VVpI1L-GFP, a GFP expression cassette under the vaccinia virus
I1L promoter (Liu et al., 2004), was inserted. CPXVD203-infected CV-1 cells
were transfected with the targeting plasmids, and the recombinant viruses
were isolated from GFP-positive plaques. Desired mutations were confirmed
by PCR.
A transient dominant selection (TDS) method was adapted to generate
CPXVD12, CPXVD12D203, and the revertant CPXVR12R203. Two selection
cassettes, VVpI1L-GFP and the vaccinia virus 7.5K promoter-driven gpt,
were inserted into pBluscriptII, generating a selection plasmid we termed
pTDS. 50 and 30 flanking sequences of CPXV12 were amplified and sewn
together by PCR and were inserted into the pTDS. This plasmid, pTDSD12,
was transfected into CV-1 cells that were infected with wtCPXV or CPXVD203
to generate CPXVD12 or CPXVD12D203, respectively. To generate
CPXVR12R203, CPXV12 and CPXV203 were sequentially reverted from
CPXVD12D203. Targeting plasmids, pTDSR12 and pTDSR203, were con-
structed by cloning the genomic segments spanning CPXV12 or CPXV203
(from 500 bp upstream to 500 bp downstream of the coding sequence) into
pTDS, respectively. First, CPXV12 locus was reverted by transfecting
pTDSR12 into CPXVD12D203-infected CV-1 cells, generating CPXVR12D203.
CPXVR12D203-infected CV-1 cells were then transfected with pTDSR203 to
generate CPXVR12R203.
Retroviral Transduction
CPXV12 was cloned from CPXV genomic DNA into pMXsIG (T. Kitamura,
University of Tokyo), a retroviral expression vector with internal ribosomal entry
site followed by GFP, which was then transfected into Plat-E cells (T. Kitamura,
University of Tokyo) using FuGENE6 (Roche). The gene encoding BHV-1
UL49.5 was cloned into the pLZRSDNGFR vector as described (Koppers-Lalic
et al., 2005). Recombinant virus was made using the Phoenix amphotropic
packaging system. Culture supernatant containing retrovirus was used to
infect C1498 cells in the presence of 5 mg/ml of hexadimethrine bromide
(Sigma) or 12 mg/ml of retronectin (Takara). UL49.5-transduced cells express-
ing DNGFR were selected using a FACSVantage cell sorter (BD Biosciences).
Metabolic Labeling
Cells were depleted of Met and Cys for 30 min and labeled with EasyTag
Express 35S protein-labeling mix (PerkinElmer) for 10 min at 200 mCi/ml. Radio-
active medium was immediately removed by centrifugation, and the labeled
cells were chased in the presence of excess Met and Cys (5 mM each) for
the indicated periods of time. Cells were washed extensively and subjected
to immunoprecipitation.430 Cell Host & Microbe 6, 422–432, November 19, 2009 ª2009 ElsImmunoprecipitation
Cells were lysed in 1% NP-40 (Sigma) in Tris-buffered saline (TBS) (10 mM Tris
[pH 7.6], 150 mM NaCl) with protease inhibitor cocktail (Roche). For the coim-
munoprecipiation experiments, TBS containing 1% digitonin (Wako) and
20 mM iodoacetamide (Sigma) was used for cell lysis. Postnuclear lysate
was incubated for 2 hr at 4C with protein A agarose (RepliGen) that was pre-
incubated with one of the following antibodies: rabbit anti-Kb serum, rabbit
anti-mouse TAP1 serum (Lybarger et al., 2003), or anti-HA 16B12 (Covance).
Where indicated, eluted proteins were treated with 10 mU of Endoglycosidase
H (Roche) for 2 hr at 37C prior to SDS-PAGE.
Immunoblotting
Proteins separated by SDS-PAGE were transferred on the PVDF membranes
(Millipore). Blots were incubated with one of the following primary antibodies,
rabbit anti-Kb serum, rabbit anti-TAP1 serum, rabbit anti-calreticulin (Stress-
gen), or rabbit anti-HA (Covance), in combination with horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (Amersham Biosciences). To detect
tapasin, blots were incubated with hamster anti-mouse tapasin 5D3 followed
by biotinylated goat anti-hamster Ig and HRP-streptavidin. Band intensities on
the films were quantified by ImageQuant TL software (Amersham Biosci-
ences).
Measuring MHC Class I Thermostability
Cells were metabolically labeled for 10 min as described and chased for
30 min. After stringent washing, cells were lysed with ice-cold TBS containing
1% NP-40. Lysates were incubated with 0, 102, 104 nM of VNVDYSKL peptide
at 4C for 1 hr, followed by incubation at 37C for 30 min. Lysates were cooled
on ice for 5 min and subjected to immunoprecipitation with anti-Kb antibody
B8-24-3 (ATCC).
Peptide Transport Assay
Cells were permeabilized using Streptolysin-O (Murex Diagnostics) at 37C for
10 min, followed by incubation with 4.5 mM of the fluorescein-conjugated
synthetic peptide CVNKTERAY (N-core glycosylation site underlined) in the
presence of 10 mM ATP or 0.125 M EDTA at 37C for 10 min. Peptide trans-
location was terminated by adding ice-cold lysis buffer containing 1% Triton
X-100. Glycosylated peptides were retrieved from postnuclear lysates by incu-
bation with concanavalin A Sepharose beads (GE Healthcare) for 2 hr at 4C.
After washing, peptides were eluted from the beads with elution buffer
(500 mM mannopyranoside, 10 mM EDTA, 50 mM Tris HCl [pH 8.0]) for 1 hr
at room temperature. Fluorescence was measured using a Mithras LB 940
multilabel reader (Berthold Technologies).
Mice, Infection, and Depletion of CD8 T Cells
Female C57BL/6 mice were purchased from National Cancer Institute. Mice
were maintained under specific pathogen-free conditions and used when
they were 9 weeks old. Mice under anesthesia were inoculated intranasally
with 20 ml of virus diluted in PBS. Survival was monitored for 4 weeks following
infection. For CD8-depletion studies, 1 mg of H35, a monoclonal antibody
specific for CD8b (Smith and Allen, 1991), or SFR3-DR5 (ATCC HB-151), an
IgG2b isotype control, was administered to each mouse intraperitoneally every
fourth day starting 2 days prior to CPXV infection. Depletion efficiency was
>95%, as determined by flow cytometry. Animal studies were approved by
the Animal Studies Committee at Washington University in St. Louis.
IFN-g Production Assay and Cytotoxicity Assay
C57BL/6 mice were intranasally infected with 13 104 PFU of CPXV, and sple-
nocytes were harvested at day 7 postinfection. MC57G cells were mock
infected or infected with wtCPXV, CPXVD12, CPXVD203, or CPXVD12D203
at a multiplicity of infection (moi) of 2 and were harvested at 16 hr postinfection.
To measure IFN-g production by CD8 T cells, we incubated splenocytes (1 3
106) with MC57G cells (33 105) for 1 hr and then further incubated in the pres-
ence of GolgiPlug (BD Biosciences) for an additional 6 hr. Cells were stained
for CD3, CD8, and intracellular IFN-g and analyzed by flow cytometry. For
cytotoxicity assays, 51Cr-labeled MC57G cells (1 3 105) were incubated with
splenocytes at different effector-to-target ratios for 4 hr. 51Cr release was
measured using a g-counter. Percent lysis was calculated by 100 3 (experi-
mental release  spontaneous release)/(maximum release  spontaneousevier Inc.
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from the targets alone, and maximum release represents the counts from
NP-40-lysed target cells.
One-Step Growth Curve
Vero cells were infected with wtCPXV, CPXVD12D203, or CPXVR12R203 at
a moi of 5. Cells were harvested at 1, 8, 12, and 24 hr postinfection, and
CPXV genome copy numbers were quantified by quantitative PCR as
explained below.
Quantification of CPXV Genome Copy Number
CPXV genome copy was quantified by quantitative PCR with a forward primer
(50-CGGCTAAGAGTTGCACATCCA-30) and a reverse primer (50-TCTGCTCC
ATTTAGTACCGATTCTAG-30) hybridized at positions 2048–2068 and 2092–
2118, respectively, and a probe (50-AGGACGTAGAATGATCTTGTA-30) at
position 2070–2091. Serial 10-fold dilutions of the positive-control plasmid,
which was generated by cloning the amplicon (2048–2118) into pBluscriptII,
were used to derive a standard curve for quantification. For splenic virus titers,
spleens were harvested at day 7 or 10 postinfection, weighed individually,
homogenized in Eagle’s minimum medium (Cellgro) containing 2% fetal calf
serum, and kept frozen until use. Upon thawing, genomic DNA was purified
using DNeasy Blood & Tissue kit, and genome copy numbers were determined
by quantitative PCR.
SUPPLEMENTAL DATA
Supplemental Data include one figure, Supplemental Experimental Procedures,
and Supplemental References and can be found with this article online at http://
www.cell.com/cell-host-microbe/supplemental/S1931-3128(09)00350-3.
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